{"DataElement":{"publicId":"13722279","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Dose Reduced Reason Other Specify","preferredDefinition":"The free-text field to describe another reason why the filgrastim or bioequivalence agent dose was reduced.","longName":"13722239v1.00:2666713v2.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"13722239","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Dose Reduced Reason","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.:An explanation of the cause of some phenomenon or action.","longName":"13722238v1.00:2390595v1.00","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"13722238","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Dose Reduced","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","longName":"13722238v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose Reduced","conceptCode":"C49505","definition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9E2F47-E87B-742A-E053-731AD00A6EBF","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2390595","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE52ECB4-C378-617F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-16","modifiedBy":"ONEDATA","dateModified":"2005-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9E2F47-E87C-742A-E053-731AD00A6EBF","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was another reason why the filgrastim or bioequivalence agent dose was reduced?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Specify other reason(s) for dose reduction:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9E9EC8-F1F1-082D-E053-731AD00A33EE","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}